** Pradaxa® (Dabigatran etexilate) 150 mg 30 hard capsules.
– Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF) with one or more risk factors, such as prior stroke or transient ischemic attack (TIA); age >/= 75 years; heart failure (NYHA Class >/= II); diabetes mellitus; hypertension.
– Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.
Each hard capsule contains:
172.95 mg dabigatran etexilate mesilate equivalent to 150 mg dabigatran etexilate.
** Any unused product or waste material should be disposed of in accordance with local requirements.
** Medical products subject to medical prescription.
** Do not chew. Read the package leaflet before use.
** Store below 30 degrees C. Store in the original package in order to protect from moisture.
Keep out of the reach and sight of children.
** Manufactured by: Boehringer Ingelheim Pharma GmbH && Co. KG, Ingelheim am Rhein – Germany
For: Boehringer Ingelheim International GmbH, Ingelheim am Rhein – Germany
استيراد : الشركة المصرية لتجارة الأدوية